AU2254692A - Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron - Google Patents

Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron

Info

Publication number
AU2254692A
AU2254692A AU22546/92A AU2254692A AU2254692A AU 2254692 A AU2254692 A AU 2254692A AU 22546/92 A AU22546/92 A AU 22546/92A AU 2254692 A AU2254692 A AU 2254692A AU 2254692 A AU2254692 A AU 2254692A
Authority
AU
Australia
Prior art keywords
ondansetron
administered
composition according
pharmaceutically acceptable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22546/92A
Other languages
English (en)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU2254692A publication Critical patent/AU2254692A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU22546/92A 1991-06-26 1992-06-25 Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron Abandoned AU2254692A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US721723 1985-04-10
US72172391A 1991-06-26 1991-06-26
US75080191A 1991-08-27 1991-08-27
US750801 2000-12-28

Publications (1)

Publication Number Publication Date
AU2254692A true AU2254692A (en) 1993-01-25

Family

ID=27110471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22546/92A Abandoned AU2254692A (en) 1991-06-26 1992-06-25 Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron

Country Status (5)

Country Link
EP (1) EP0591395A1 (enExample)
JP (1) JPH06509073A (enExample)
AU (1) AU2254692A (enExample)
CA (1) CA2112488A1 (enExample)
WO (1) WO1993000075A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
CN1078465C (zh) * 1996-10-10 2002-01-30 沈阳药科大学 一种含奥坦西酮的透皮吸收制剂
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
WO2006085497A1 (ja) * 2005-02-09 2006-08-17 Kissei Pharmaceutical Co., Ltd. 口腔内崩壊錠
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518745D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
DE3782028T2 (de) * 1986-12-17 1993-02-18 Glaxo Group Ltd Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.

Also Published As

Publication number Publication date
JPH06509073A (ja) 1994-10-13
EP0591395A1 (en) 1994-04-13
EP0591395A4 (enExample) 1994-08-31
CA2112488A1 (en) 1993-01-07
WO1993000075A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
US5470868A (en) Methods for treating emesis and nausea using optically pure R(+) ondansetron
US5786357A (en) Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US5942503A (en) Use of Epinastine for the treatment of pain
EP0663828B1 (en) Treating allergic rhinitis and asthma using (-) Cetirizine
KR100422492B1 (ko) 중추신경계 질환을 치료하는데 유용한 광학적으로 순수한 (+)노르시사프라이드
EP1145715A2 (en) Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CN101588804A (zh) 治疗或防治激素变异症状的方法
CA2139636A1 (en) Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU2254692A (en) Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
KR20010071047A (ko) 위장-식도 역류 질환을 치료하는데 이용할 수 있는 조성물및 그 방법
WO1993010787A1 (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
AU3675299A (en) Methods and compositions for treating emesis, nausa and other disorders using optically pure R(+) ondansetron
AU3143402A (en) Methods and compositions for treating emesis, nausea and other disorders using optically pure R() ondansetron
IE903278A1 (en) Use of dopamine-autoreceptor agonists in the treatment of¹drug dependency
US4904673A (en) Agent for treating bradycardia and bradyarrhythmia
WO1993010788A1 (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
DE69625819T2 (de) Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
AU717432B2 (en) Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2147357A1 (en) Methods and compositions (+) doxazosin for the treatment of hypertension
JPH01168615A (ja) 制吐作用薬剤
MXPA98003206A (en) Employment of epinastin for the treatment of dolo
AU2004200165A1 (en) Methods and compositions for treating gastro-esophageal reflux disease